Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

Date
The Workshop on Development of Tissue-Agnostic, Biomarker-Based Indications, cohosted by ASCO, FDA, and Friends of Cancer Research, is now open for registration. The April 26 full-day event aims to bring together members of various sectors to identify clinical trial designs and strategies that can accelerate drug development based on biomarkers that are agnostic to tumor types. Learn more and register.
The ASCO Annual Meeting, taking place May 31-June 4 in Chicago, IL is the premier multidisciplinary conference for global cancer care. Collaborate with and learn from world-renowned faculty discussing state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. Meet with fellow clinicians and researchers, share ideas, and build foundations for future relationships. Register by April 24 for the best rates.
The U.S. Food and Drug Administration is alerting health care professionals, oncology clinical investigators and patients about the risks associated with the investigational use of Venclexta (venetoclax) for the treatment of patients with multiple myeloma based on data from a clinical trial. Venclexta is not approved for the treatment of multiple myeloma. Read more. 
On February 28, ASCO joined the American Medical Association (AMA) and over 90 other groups in sending a letter to CMS urging them to provide guidance to Medicare Advantage (MA) plans on prior authorization processes.
 ASCO responded to a request for information (RFI) that the Senate Health Education, Labor and Pensions Committee issued in December to providers, insurers, and other groups to help identify specific ideas about how to reduce healthcare costs for consumers.  ASCO's response included the following: 
“We strongly oppose the White House budget proposal for Fiscal Year (FY) 2020, which would stall our nation’s progress against cancer and impede access to needed care for the millions of Americans dealing with cancer. The proposal would make drastic, unprecedented cuts to the U.S. Department of Health and Human Services—which houses the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Centers for Medicare & Medicaid Services (CMS).
On March 18, 2019, the Food and Drug Administration approved atezolizumab (TECENTRIQ®, Genentech Inc.) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). Read more. 
On April 10, ASCO will convene some of the nation’s top physicians, advocates and rural health experts for a discussion on the challenges facing Americans living with cancer in rural areas and promising approaches to improve outcomes. This event will explore a wide range of topics, including: